Aly Abdalla, Ronnebaum Sarah, Patel Dipen, Doleh Yunes, Benavente Fernando
AstraZeneca, Gaithersburg, MD 20878, USA.
Pharmerit - an OPEN Health Company, Bethesda, MD 20814, USA.
Hepat Oncol. 2020 Jul 21;7(3):HEP27. doi: 10.2217/hep-2020-0024.
To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA.
MATERIALS & METHODS: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanistic burden studies published 2008-2018 were systematically searched.
HCC incidence was 9.5 per 100,000 person-years in most recent data, but was ∼100-times higher among patients with hepatitis/cirrhosis. Approximately a third of patients were diagnosed with advanced disease. Patients with HCC experienced poor quality of life. Direct costs were substantial and varied based on underlying demographics, disease stage and treatment received. Between 25-77% of patients did not receive surgical, locoregional or systemic treatment.
Better treatments are needed to extend survival and improve quality of life for patients with HCC.
描述美国肝细胞癌（HCC）的流行病学、人文和经济负担。
系统检索2008 - 2018年发表的关于全国队列的流行病学和经济负担、任何经济模型或任何人文负担研究的文献。
最新数据显示，HCC发病率为每10万人年9.5例，但在肝炎/肝硬化患者中高出约100倍。约三分之一的患者被诊断为晚期疾病。HCC患者生活质量较差。直接成本巨大，且因基础人口统计学特征、疾病阶段和接受的治疗而异。25% - 77%的患者未接受手术、局部或全身治疗。
需要更好的治疗方法来延长HCC患者的生存期并改善其生活质量。
